Translate this page into:
Regiospecific synthesis by copper- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer and anti-inflammatory activities of oleanolic acid triazole derivatives
⁎Corresponding author. Tel.: +216 73500279; fax: +216 73500278. hich.benjannet@yahoo.fr (Hichem Ben Jannet)
-
Received: ,
Accepted: ,
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.
Peer review under responsibility of King Saud University.
Abstract
The oleanolic acid (1), a natural pentacyclic triterpenoid, was quantitatively isolated from pomace olive (Olea europaea L.) under ultra-sonication conditions (6.8 g (3.4 mg/g DW)). Two series of oleanolic acid-1-phenyl-1H-[1,2,3]triazol-4-ylmethylester 6a–g and new oleanolic acid-1-phenyl-1H-[1,2,3]triazol-5-ylmethylester 7a–g congeners have been designed and synthesized in an attempt to develop potent anticancer and anti-inflammatory agents. A facile and regiospecific synthesis of 1,2,3-triazoles catalyzed by Cu(I) (CuAAC) or Ru(II) (RuAAC) and conducted under microwave conditions of oleanolic acid–alkyne derivative 5 with various aromatic azides 2a–g afforded a series of 1,4- and 1,5-triazolyl derivatives, respectively. Their structures were confirmed by using 1H NMR, 13C NMR, NOESY and HRMS analysis. Most of the compounds were evaluated for their anticancer and anti-inflammatory activities. Oleanolic acid 1 exhibited promising anticancer activity against murine breast (EMT-6) and human colon (SW480) cancer cells. Its derivatives 6b and 6c (1,4-regioisomers) and 7b (1,5-regioisomer) were found to be anti-cancer agents. On the other hand, only 6b displays anti-inflammatory activity.
Keywords
Oleanolic acid
Triazoles
Click-chemistry
Microwave
Anticancer activity
Anti-inflammatory activity
1 Introduction
A review of the literature showed that some triterpenes and their derivatives have been associated with various pharmacological activities. They have shown good antitumoral (Schwarz and Csuk, 2010), antioxidant (Chiung et al., 2010), anti-inflammatory (Bednarczyk-Cwynar et al., 2012), antiviral (Grishko et al., 2014), antibacterial and antifungal (Chouaïb et al., 2015; Hichri et al., 2003) activities.
Oleanolic acid (3β-hydroxyolean-12-en-28-oic acid, 1) is a natural pentacyclic triterpenoid compound (Fig. 1), widely distributed throughout the vegetable kingdom (Guo et al., 2015; Liu, 2005). This compound and some of its derivatives have been reported to possess various biological activities such as anticancer (Srivastava et al., 2010), gastroprotective (Sánchez et al., 2006), anti-Alzheimer (Abdalla et al., 2012), antidiabetic (Chen et al., 2006), hepatoprotective (Yim et al., 2001) and many other important activities. Thus all the pharmacological properties of oleanolic acid were reviewed by Liu (1995), who mentioned also its hepatoprotective, anti-neoplastic and anti-hyperlipidemic properties and emphasized its low toxicity. Similarly, oleanolic acid has been marketed in China as an oral drug for human liver disorders (Liu, 2005).
On the other hand, triazoles, an important class of N-heterocycles, are employed in many pharmaceutical products (Farajzadeh and Khoshmaram, 2013). In particular, 1,2,3-triazoles are of great importance in medicinal chemistry because they can act as pharmacophores and linkers between two or more substances of interest in molecular hybridization approaches (Agalave et al., 2011). 1,2,3-Triazoles are among heterocyclic compounds that attract the attention of organic chemists (Singh et al., 2010) due to their broad spectrum of applications in biochemical, medicinal chemistry and material sciences. Several of these triazoles are drugs and have a wide range of biological activities such as anti-HIV (Kirschberg et al., 2008), antiviral (Aufort et al., 2008), cytotoxic (Kamal et al., 2008) and antibacterial (Wang et al., 2010) effects. Rashid et al. (2013) suggest that ursolic acid–triazolyl derivatives show an anticancer activity against a panel of human cancer cell lines including A-549 (lung), MCF-7 (breast), HCT-116 (colon), THP-1 (leukemia) and a normal epithelial cell line (FR-2) using sulforhodamine-B assay. Most of these compounds exhibited better anticancer activity against all the tested cancer cell lines compared to positive controls, 4,5-fluorouracil and mitomycin-C. According to previous reports, it has been observed that keeping polar substituents at the C-28 position of the triterpene skeleton enhanced its anti-tumor potential against BGC-823 cell lines (Bai et al., 2011). Recently, Wei et al. (2015) suggest that the incorporation of a 1,2,3-triazole moiety at C-28 position of oleanolic acid 1 was useful to improve its cell proliferation inhibition against human cancer cell lines.
The 1,3-dipolar cycloaddition is considered the most important and versatile synthetic route for a wide range of 1,2,3-triazoles and triazolines. The conventional synthesis of 1,2,3-triazoles relies on the Huisgen [3 + 2] cycloaddition between alkynes and organic azides usually provides a mixture of 1,4- and 1,5-disubstituted regioisomers (Norris et al., 1996; Talekar and Wightman, 1997). In general, the attempts to separate these regioisomers by chromatography, with some exceptions, were not successful. The growing use of catalyzed azide–alkyne cycloaddition named the “click” reaction, allowing the easy access to regiospecific 1,2,3-triazoles, motivated their use in the drug discovery field (Giffin et al., 2008). In view of the preceding literature data, we were encouraged to synthesize oleanolic acid-(C-28)triazolyl derivatives as a contribution to develop more effective therapeutic agents by employing click chemistry protocol. Click chemistry enables a modular approach to generate these novel pharmacophores utilizing a collection of reliable chemical reactions. The Huisgen 1,3-dipolar cycloaddition of alkynes and azides (AAC) has appeared as a powerful linking reaction to give substituted-1,2,3-triazoles. This reaction when catalyzed with Copper (I) (CuAAC) leads exclusively to the 1,4-regioisomer (Kumar et al., 2009). On the other hand, the ruthenium-catalyzed version of the reaction (RuAAC), affords mainly the 1,5-regioisomer (Takasu et al., 2010).
We report herein the synthesis of 1,4- and new 1,5-disubstituted-1,2,3-triazole derivatives from oleanolic acid 1 (Fig. 1) isolated from pomace olive (Olea europaea L.) cultivar: Chemlali, under ultra-sonication conditions (6.8 g (3.4 mg/g DW)) (Chouaïb et al., 2015). They are prepared via well established Cu(I)-catalyzed azide–alkyne (CuAAC) and Ru(II)-catalyzed azide–alkyne (RuAAC) cycloadditions which were conducted for the first time under microwave and solvent free conditions. Oleanolic acid 1 and most obtained derivatives were evaluated for their anticancer and anti-inflammatory activities in vitro.
2 Results and discussion
The precursors 2a–g were synthesized from the appropriate anilines using a two-step procedure by diazotization with sodium nitrite in acidic conditions followed by displacement with sodium azide. The desired aromatic azides 2a–g were obtained in yields ranging from 85% to 98%. On the other hand, compound 1 was subjected to oxidation using Jones reagent at 0 °C that resulted in the formation of C-3 oxidized derivative 3 in quantitative yield (94%). The propargylation of the carboxyl group at C-28 in dry DMF using NaH as catalyst provided the propargylated ester 4 in excellent yield (98%). The 3-oxo group of Compound 4 was selectively reduced to C-3 hydroxyl group with sodium borohydride under microwave irradiation (250 W, 3 min), to obtain the dipolarophile 5 in 99% yield (Scheme 1).![Synthesis of the 1,4- and 1,5-triazolyl (6a–g, 7a–g) derivatives. Reagents and conditions: (a) Jone’s oxidation (CrO3, H2SO4/acetone), 0 °C, 94%, (b) propargyl bromide, NaH, dry DMF, rt, 98%, (c) NaBH4, CH3OH/THF, Microwave (250 W, 3 min), 99%, (d) Cuprous iodide (CuI), Et3N, solvent free, Microwave (200 W, 2–4 min), 87–98%, (e) [Cp∗RuCl(PPh3)2], DMF, Microwave (250 W, 3–6 min), 84–96%.](/content/184/2019/12/8/img/10.1016_j.arabjc.2015.12.013-fig2.png)
Although the Cu(I)-catalyzed Huisgen 1,3-dipolar cyclization usually proceeds in high yields, it has been reported to be highly dependent on the substrate and reaction conditions. Using phenylazide (2a, R = H) as a model azide, the most suitable conditions to carry out the cyclization with alkyne 5 were explored. The use of 2 equiv of phenylazide is here necessary because of its possible dimerization into secondary amine (Lange et al., 1998; An et al., 2004). The most relevant results of this study are shown in Table 1.
As shown in Table 1 0.5 equiv of CuI under microwave and solvent free conditions in the presence of triethylamine as a base (1 equiv. referred to the starting alkyne) was essential to obtain the higher yield of the desired 1,2,3-triazole in minimum reaction time (entry 5). Interestingly, a further increase in the amount of CuI did not improve the yield (entry 6). However, the excess of Cu(I) probably caused a diminution in the performance due to the deposition of copper species on the dipole and the low solubility of cuprous iodide in triethylamine. The optimal condition (Table 1, entry 5) found was applied in a regiospecific approach using Huisgen 1,3-dipolar cycloaddition reaction (CuAAC) of the alkyne 5 with various aromatic azides 2a–g in the presence of cuprous iodide (CuI) and Et3N resulting into the formation of regiospecific 1,4-substituted-triazolyl derivatives 6a–g in excellent yields (Scheme 1).
All the reactions were carried under microwave irradiation (200 W) completed within 2–4 min. The desired compounds 6a–g were obtained in yields ranging from 87% to 98% under microwave and solvent free conditions. This method compared to that cited in the literature (Wei et al., 2015) for the preparation of the same compounds has the advantage of being simple and the products can be obtained from the reaction mixture by simple extraction.
The structure of the 1,4-substituted triazole regioisomers were evidenced by their spectral data. The 1H NMR spectra of compounds 6a–g showed a singlet at δH 7.96–8.02 attributable to the proton H-5 of the triazole moiety and signals at the aromatic region (δH 7.00–7.70) relative to the aromatic protons introduced by the azides used. These structures were further supported by 13C and DEPT NMR spectra, which showed all the expected carbon signals corresponding to oleanolic acid–triazolyl derivatives, essentially the aromatic carbons resonating at δC 114.2–159.3 introduced by the azides used.
The resulting 1,4-regioisomers were evidenced from the NOE between H-5triazole/Hmethylene and H-5triazole/Harom, and the absence of NOE between Hmethylene/Harom, and such regiospecificity agrees with that cited in the literature (Kumar et al., 2009; Li et al., 2014). High Resolution Mass Spectrometry (HRMS) data of all the formed derivatives were also in agreement with the proposed structures.
On the other hand, we turned our attention to the ruthenium–catalyzed version of the reaction (RuAAC), which is less extensively described and led mainly to 1,5-regioisomers (Boren et al., 2008). Generally, the common approaches to 1,5-regioisomers were based on Grignard reagents (Krasinski et al., 2004), or 1-trimethylsilylalkynes (Coats et al., 2005). Microwave heating allows a significant acceleration of the reaction from 8 h to 2 min (Table 1). Working under microwave irradiation in DMF, we first investigated the optimal conditions for the cycloaddition of alkyne 5 and phenylazide 2a using different concentrations of the catalyst Cp∗RuCl(PPh3)2 (Table 2).
| Entry | Catalyst (mol%)b | Solvent | Irradiation time (min) | Conversion (%) |
|---|---|---|---|---|
| 1 | 1 | DMF | 10 | 50 |
| 2 | 3 | DMF | 10 | 80 |
| 3 | 5 | DMF | 4 | 100 |
| 4 | 5 | Solvent free | 10 | No reaction |
The total conversion of oleanolic acid–alkyne derivative 5 was obtained after only 4 min of reaction with 5% catalyst (entry 3). For lower catalyst loading, conversion was not complete, even after 10 min reaction (Table 2, entries 1 and 2). Moreover, when we worked under solvent free conditions, there was no reaction (entry 4).
With these optimized conditions in hand, the dipolarophile 5 was reacted with various aromatic azides and 5 mol% Cp∗RuCl(PPh3)2 catalyst. All the reactions were performed under microwave conditions in DMF and completed within 3–6 min. The desired new compounds 7a–g were obtained in yields ranging from 84% to 96% (Scheme 1).
The reaction was conducted with complete regiospecificity and most of the yields remained good for the whole synthetic sequence. The structure of the prepared compounds (7a–g) was established on the basis of their analytical data.
In addition of the signals corresponding to the protons introduced by oleanolic acid–alkyne 5, new signals related to the azides used were observed in 1H NMR spectra. Examination at 300 MHz showed in particular a singlet at δH 7.82–8.17 (H-4 of the triazole ring) and also other signals at δH 7.05–7.93 (aromatic protons). The 13C NMR spectra confirmed the above spectral data by the observation of new signals at δC 114.2–160.1 relative to the aromatic carbons and the triazoles formed.
The 1,5-regiochemistry thus adopted was confirmed by NOESY spectra showing the NOE between H-4triazole/Hmethylene and Hmethylene/Harom, and the absence of NOE between H-4triazole/Harom, and such observation was in agreement with the proposed structures and with that indicated in the literature (Takasu et al., 2010). The HRMS data of the formed compounds 7a–g were in concordance with the established structures.
3 Anticancer activity
The cytotoxic activity of oleanolic acid 1 and most of its triazole derivatives were studied using cultured murine EMT-6 (Breast) and human SW480 (colon) cancer cell lines. Doxorubicin, etoposide, 5-fluorouracil and methotrexate (10 μM) were used as anticancer references in this study. Compounds 6b (4-OCH3) and 6c (4-Cl) (1,4-regioisomers) and 7b (4-OCH3) (1,5-regioisomer) were found to be the most promising. From the percentage viability and IC50 data (Tables 3 and 4) and compared to most of its derivatives, oleanolic acid 1 displayed the highest anticancer activity, exhibiting potent anti-proliferative activity toward breast (EMT-6) (Viability (%/Control) = 7% (100 μM); IC50 = 66.6 ± 0.7 μM) and colon (SW480) (Viability (%/Control) = 13% (100 μM); IC50 = 76.0 ± 3.0 μM) cancer cells. The anticancer activity of oleanolic acid 1 disappeared at lower concentrations (30 and 10 μM). The results given in Tables 3 and 4, show that the junction of oleanolic acid 1 to triazole according to the two regiochemistry approaches (1,4- and 1,5-) through the linker methylene did not improve its anticancer activity.
| Tissue | Breast | Colon | ||
|---|---|---|---|---|
| Cell line | EMT-6 | SW480 | ||
| Conc. (μM) | Viability (% /Control) | |||
| DMSO 0.33% (Control) | 100 ± 2 | 100 ± 2 | ||
| Doxorubicin | 10 | 6 ± 0 | 25 ± 1 | |
| Etoposide | 10 | 41 ± 2 | 70 ± 5 | |
| 5-Fluorouracil | 10 | 26 ± 1 | 92 ± 2 | |
| Methotrexate | 10 | 14 ± 0 | 68 ± 0 | |
| Entry | Code | |||
| 1 | 1(OA) | 100 | 7 ± 0 | 13 ± 1 |
| 30 | 97 ± 2 | 121 ± 2 | ||
| 10 | 94 ± 0 | 114 ± 6 | ||
| 2 | 6b | 100 | 46 ± 4 | 66 ± 4 |
| 30 | 81 ± 6 | 93 ± 0 | ||
| 10 | 113 ± 0 | 100 ± 0 | ||
| 3 | 6c | 100 | 42 ± 4 | 15 ± 0 |
| 30 | 66 ± 5 | 49 ± 0 | ||
| 10 | 97 ± 2 | 91 ± 5 | ||
| 4 | 6e | 100 | 78 ± 8 | 108 ± 5 |
| 30 | 112 ± 1 | 133 ± 2 | ||
| 10 | 107 ± 0 | 120 ± 6 | ||
| 5 | 6f | 100 | 102 ± 1 | 112 ± 1 |
| 30 | 109 ± 1 | 106 ± 1 | ||
| 10 | 106 ± 0 | 110 ± 5 | ||
| 6 | 6g | 100 | 106 ± 2 | 104 ± 4 |
| 30 | 101 ± 0 | 104 ± 2 | ||
| 10 | 100 ± 1 | 106 ± 6 | ||
| 7 | 7b | 100 | 41 ± 2 | 66 ± 0 |
| 30 | 77 ± 1 | 85 ± 4 | ||
| 10 | 103 ± 2 | 113 ± 9 | ||
| 8 | 7c | 100 | 94 ± 3 | 102 ± 0 |
| 30 | 104 ± 3 | 121 ± 4 | ||
| 10 | 114 ± 1 | 120 ± 1 | ||
| 9 | 7e | 100 | 74 ± 3 | 105 ± 0 |
| 30 | 95 ± 0 | 107 ± 1 | ||
| 10 | 96 ± 4 | 101 ± 1 | ||
| 10 | 7f | 100 | 60 ± 1 | 80 ± 1 |
| 30 | 92 ± 0 | 107 ± 3 | ||
| 10 | 97 ± 0 | 117 ± 4 | ||
| IC50 (μM) | |||
|---|---|---|---|
| Tissue | Breast | Colon | |
| Cell line | EMT-6 | SW480 | |
| Anticancer drug | |||
| Doxorubicin | 5.3 ± 0.1 | 6.8 ± 0.6 | |
| Etoposide | 8.5 ± 1.0 | 27.8 ± 2.6 | |
| 5-Fluorouracil | 6.8 ± 0.6 | >40 | |
| Methotrexate | 5.8 ± 0.2 | >40 | |
| Entry | Code | ||
| 1 | 1(OA) | 66.6 ± 0.7 | 76.0 ± 3.0 |
| 2 | 6b | 91.8 ± 3.3 | >100 |
| 3 | 6c | 76.0 ± 3.7 | 29.6 ± 1.7 |
| 4 | 6e | >100 | >100 |
| 5 | 6f | >100 | >100 |
| 6 | 6g | >100 | >100 |
| 7 | 7b | 82.8 ± 1.7 | >100 |
| 8 | 7c | 94 ± 3 | >100 |
| 9 | 7e | 74 ± 3 | >100 |
| 10 | 7f | 60 ± 1 | >100 |
For the 1,4-regioisomers, compounds 6b and 6c exhibited the highest anticancer activity against breast cancer cells (IC50 = 91.8 ± 3.3 and 76.0 ± 3.7 μM, respectively). Toward colon cell lines, only 6c displayed a remarkable effect (IC50 = 29.6 ± 1.7 μM), and it was found more than twice as active as oleanolic acid 1 (IC50 = 76.0 ± 3.0 μM). The positive mesomeric effect (+M) of the methoxy group in 6b and chlorine atom in 6c may explain their activity compared to that of the rest of analogues from the same series. In the contrary, in the case of compounds 6e, 6f and 6g, the presence of 4-NO2–C6H4, 3-CH3–C6H4 and naphthyl, respectively attached to their triazole moieties appears to reduce considerably the anticancer activity against the two cancer cell lines used.
For the 1,5-regioisomers, only 7f, bearing a 3-CH3–C6H4 in its triazole moiety, was found to be most active against Breast (EMT-6) cells (Viability (%/Control) = 60 ± 1% (100 μM); IC50 = 60 ± 1 μM) followed by 7e (4-NO2) (Viability (%/Control) = 74 ± 3% (100 μM); IC50 = 74 ± 3 μM). Compound 7b (4-OCH3–C6H4) and 7c (4-Cl–C6H4) displayed less activity than 7f and 7e against the same cell line ((IC50 = 82.8 ± 1.7 and 94 ± 3 μM, respectively).
These results showed clearly the contribution of the nature of the aromatic system attached to the triazole ring in this activity.
All compounds 7 tested did not exhibit any activity toward the used cancer cell lines (IC50 > 100 μM) toward (SW480) colon cancer cell lines.
The results obtained show that the difference in activity of the regioisomers 6 (1,4-) and 7 (1,5-) is undoubtedly due to both the regiochemistry and the nature of the substituent borne by the aromatic ring attached to the triazole.
4 Anti-inflammatory activity
The anti-inflammatory activity of the tested compounds was studied using LPS-stimulated human peripheral blood mononuclear cells (PBMCs). Three anti-inflammatory references were tested in the same conditions: ZVAD (5 μM), dexamethasone (DEXA, 1 μM) and prednisolone (PRED, 70 μM). Secretion IL-1β was measured only in the culture supernatants of PBMCs treated with compounds that showed no or low toxicity, using a sandwich enzyme-linked immunosorbent assay (ELISA) method (eBioscience, San Diego, USA), according to manufacturer instructions.
The anti-inflammatory results (Table 4) revealed that the synthesized compounds showed variable degrees of % IL-1β production. This finding showed that the introduction of the 1,4- and 1,5-triazole moieties in compound 1 did not considerably improve its anti-inflammatory activity. In the series of 1,4-regioisomers, compound 6b was found to be relatively the most active (% IL-1β production = 71 ± 15; 100 μM). The significant positive mesomeric effect (+M) of the methoxy group in para position of the aromatic ring attached to the triazole moiety in compound 6b compared to that exerted by the chlorine atom in compound 6c and by the methyl group in compound 6f at the same position may explain the difference in activity between these three derivatives. On the other hand, it has been found that compounds 6e and 6g both bearing a group with a negative mesomeric effect (−M) (4(NO2–C6H4) and naphtyl, respectively) did not exhibit any activity.
On the other hand, the results showed that only 7f (3-CH3; 1,5-regioisomer) (% IL-1β production = 79 ± 2; 100 μM) exhibited a slightly higher anti-inflammatory activity than oleanolic acid 1 (% IL-1β production = 88 ± 3; 100 μM). Compounds 7b, 7c and 7e were found to be not anti-inflammatory and the triazole system in its 1,5-regiochemistry has not improved remarkably the activity of oleanolic acid 1 (see Table 5).
| Conc. (μM) | % PBMCs viability (/Control) | % IL-1β production (/Control) | ||
|---|---|---|---|---|
| DMSO 0.33% + LPS (Control) | 100 ± 4 | 100 ± 2 | ||
| ZVAD + LPS | 5 | 110 ± 4 | 42 ± 2 | |
| DEXA + LPS | 1 | 81 ± 7 | 32 ± 2 | |
| PRED + LPS | 70 | 67 ± 8 | 43 ± 4 | |
| Entry | Code | |||
| 1 | 1(OA) | 100 | 73 ± 7 | 88 ± 3 |
| 30 | 73 ± 13 | Nda | ||
| 2 | 6b | 100 | 83 ± 3 | 71 ± 15 |
| 30 | 61 ± 4 | Nd | ||
| 3 | 6c | 100 | 56 ± 4 | 88 ± 1 |
| 30 | 47 ± 3 | Nd | ||
| 4 | 6e | 100 | 86 ± 10 | 95 ± 4 |
| 30 | 81 ± 9 | Nd | ||
| 5 | 6f | 100 | 80 ± 2 | 88 ± 3 |
| 30 | 61 ± 7 | Nd | ||
| 6 | 6g | 100 | 89 ± 6 | 88 ± 4 |
| 30 | 62 ± 9 | Nd | ||
| 7 | 7b | 100 | 59 ± 8 | Nd |
| 30 | 53 ± 1 | 83 ± 4 | ||
| 8 | 7c | 100 | 57 ± 20 | Nd |
| 30 | 66 ± 2 | 89 ± 1 | ||
| 9 | 7e | 100 | 56 ± 10 | Nd |
| 30 | 62 ± 3 | 104 ± 4 | ||
| 10 | 7f | 100 | 66 ± 2 | 79 ± 2 |
| 30 | 80 ± 7 | Nd | ||
5 Conclusion
In summary, oleanolic acid 1 was quantitatively isolated from pomace olive (O. europaea L.) cultivar: Chemlali (6.8 g (3.4 mg/g DW)) under ultra-sonication conditions. On the other hand, we used the Copper(I) iodide catalytic system for CuAAC and the Cp∗RuCl(PPh3)2 for RuAAC under microwave conditions to reach hitherto new natural oleanolic acid derivatives bearing 1,4 and 1,5-disubstituted triazole, respectively. The cooperative effect of the catalyst and the microwave activation afforded the desired compounds in a few minutes in high yields. This effective approach allows an easy access to a series of 1,4-regioisomers under CuAAC and 1,5-disubstituted-triazolo derivatives under RuAAC. Oleanolic acid 1 and most of the prepared derivatives were evaluated for the anticancer and anti-inflammatory activities. Oleanolic acid 1 and compounds 6c (4-Cl; 1,4-regioisomer) and 7e (4-NO2; 1,5-regioisomer) showed the highest anticancer activity against breast (EMT-6) and 6c was found more than twice as active as oleanolic acid 1 toward colon (SW480) cancer cells. In this context, the regiochemistry and the mesomeric effect appear involved in this activity. On the other hand, 6b (4-OCH3; 1,4-regioisomer) and 7f (3-CH3; 1,5-regioisomer) showed a slightly higher anti-inflammatory activity than oleanolic acid 1.
6 Experimental section
Solvents were purified and dried using standard methods. Melting points were determined on a Büchi 510 apparatus using capillary tubes. Commercial TLC plates (Silica gel 60, F254, sds) were used to monitor the progress of the reaction. Column chromatography was performed with silica gel 60 (particle size 40–63 μm, sds). HRMS spectra were acquired with an ESI-TOF (LCT Premier XE, Waters) using the reflectron mode. Leucine-enkephaline peptide was employed as a lockmass for the LockSpray. 1H (300 MHz) and 13C (75 MHz) NMR spectra were recorded on a Bruker AM-300 spectrometer, using CDCl3 and CD3OD as solvents. The microwave was a Biotage AB Initiator EXP EU with a maximum power of 800 W (2450 MHz). The chemical shifts (δ) are reported in ppm relative to the residual non-deuterated solvent as internal standard and coupling constants were measured in Hz.
6.1 General procedure for preparation of azides 2a–g
To a suspension of the appropriate anilines in a 1:1:4 mixture of H2O/HCl/ice (100 mL) was added 1.2 equiv of sodium nitrite (NaNO2), while keeping the temperature below 0 °C. After being stirred at room temperature for 30 min, 2 equiv. of sodium azide (previously dissolved in water) was added in small portions. The mixture was stirred at room temperature for 2 h, poured into water, and extracted with chloroform. The organic phase was dried over Na2SO4, and the solvent was evaporated to give the desired dipoles 2a–g, which were used directly in the 1,3-dipolar cycloaddition reactions.
6.2 Synthesis of 3-oxo-olean-12-en-28-oic acid (3)
To a solution of 1 (2.4 g, 5.2 mmol) in acetone (30 mL) at 0 °C, 5 drops of Jones reagent were added and reaction mixture was stirred at room temperature. Reaction was monitored by TLC till its completion in around 3 h. After quenching the reaction with cold water, crude product was extracted with ethyl acetate (3 × 50 mL). Organic layer was dried over sodium sulfate and purified through column chromatography to give pure 3-oxo-olean-12-en-28-oic acid (3) (2.22 g, 94% yield). White solid; mp: 287–289 °C; 1H NMR (300 MHz, CDCl3): δ 5.31 (1H, t, J = 3.1 Hz), 2.88 (1H, dd, J = 6.7; 4.2 Hz), 2.56 (1H, m), 2.40 (1H, m), 2.05–1.92 (4H, m), 1.78–1.60 (6H, m), 1.48 (2H, m), 1.42 (2H, m), 1.35–1.29 (6H, m), 1.19 (3H, s), 1.05 (3H, s), 1.16 (3H, s), 1.10 (3H, s), 0.95 (3H, s), 0.88 (3H, s), 0.83 (3H, s); 13C NMR (75 MHz, CDCl3): δ 217.1, 183.4, 143.1, 121.9, 54.8, 46.9, 46.3, 46.0, 45.8, 41.2, 40.5, 38.8, 38.6, 36.3, 33.6, 33.3, 32.5, 31.9, 31.6, 30.1, 29.1, 27.2, 25.9, 25.3, 23.0, 22.9, 22.4, 20.9, 19.0, 16.5; HRMS (ESI−): calcd. for (C30H45O3)− [M–H]− 453,3369, found 453,3390.
6.3 Synthesis of compound (4)
To a solution of 3 (2.2 g, 4.8 mmol) in dry DMF, sodium hydride (230 mg, 9.6 mmol) and propargyl bromide (1.4 g, 9.6 mmol) were added and the reaction mixture was stirred at room temperature for 2 h. Reaction was monitored by TLC and the crude product was subjected to column chromatography to give pure prop-2-yn-1-yl-3-oxo-olean-12-en-28-oate (4) (2.31 g, 98% yield). White solid; mp: 293–294 °C; 1H NMR (300 MHz, CDCl3): δ 5.25 (1H, s), 4.60 (1H, dd, J = 15.6; 2.1 Hz), 4.51 (1H, dd, J = 15.3; 2.4 Hz), 2.81 (1H, dd, J = 7.8; 4.5 Hz), 2.34 (1H, t, J = 2.4 Hz), 1.92 (2H, m), 1.79–1.70 (6H, m), 1.85 (4H, m), 1.74 (2H, m), 1.56 (4H, m), 1.47–1.33 (4H, m), 1.17 (3H, s), 1.08 (3H, s), 1.05 (3H, s), 1.01 (3H, s), 0.89 (3H, s), 0.78 (3H, s), 0.73 (3H, s); 13C NMR (75 MHz, CDCl3): δ 216.8, 176.3, 142.8, 122.4, 77.7, 73.6, 54.8, 51.2, 47.2, 46.3, 45.4, 41.2, 40.9, 38.8, 38.3, 37.6, 33.5, 33.4, 32.5, 32.2, 31.7, 30.3, 29.1, 27.8, 27.1, 26.8, 25.3, 23.2, 22.9, 22.4, 17.9, 16.8, 15.5; HRMS (ESI−): calcd. for (C33H47O3)− [M−H]− 491,3525, found 491,3561.
6.4 Synthesis of alkyne (5)
Compound 4 (2.16 g, 4.4 mmol) was dissolved in methanol and THF mixture (20 mL, 1:1) and (0.16 g, 4.4 mmol) of sodium borohydride was added. The reaction mixture was subjected to microwave irradiations at 250 W for 3 min. After reaction completion, the solvent was removed in vacuo and the residue was diluted with water (100 mL). The mixture was acidified with HCl aqueous solution (1 M) and extracted with ethyl acetate (3 × 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was chromatographed over silica gel and eluted with petroleum ether:ethyl acetate (2:1) to yield prop-2-yn-1-yl-(3β)-3-hydroxyolean-12-en-28-oate (5) (2.15 g, 99% yield). White solid; mp: 290–291 °C; 1H NMR (300 MHz, CDCl3): δ 5.23 (1H, s), 4.61 (1H, dd, J = 15.3; 2.1 Hz), 4.49 (1H, dd, J = 15.3; 2.4 Hz), 3.15 (1H, dd, J = 10.2; 4.5 Hz), 2.82 (1H, dd, J = 7.8; 4.2 Hz), 2.34 (1H, t, J = 2.4 Hz), 1.93–1.82 (4H, m), 1.64–1.49 (10H, m), 1.46–1.34 (8H, m), 1.17 (3H, s), 1.08 (3H, s), 1.05 (3H, s), 1.01 (3H, s), 0.89 (3H, s), 0.78 (3H, s), 0.73 (3H, s); 13C NMR (75 MHz, CDCl3): δ 176.3, 142.9, 122.1, 78.5, 77.6, 73.8, 54.7, 51.1, 47.1, 46.3, 45.3, 41.2, 40.8, 38.9, 38.2, 37.9, 36.5, 33.3, 32.5, 32.2, 31.7, 30.1, 27.6, 27.2, 26.7, 25.3, 23.1, 22.9, 22.5, 17.8, 16.6, 15.0, 14.8; HRMS (ESI+): calcd. for (C33H51O3)+ [M+H]+ 495,3838, found 495,3841.
6.5 General procedure for the synthesis of compounds 6a–g: Cu-catalyzed azide–alkyne cycloaddition
Under solvent free conditions 0.1 g (0.2 mmol) of dipolarophile 5, Copper(I) iodide (0.5 equiv) and triethylamine (1 equiv) were added at room temperature. To this mixture, aryl azide (0.4 mmol) was added and the reaction mixture was subjected to microwave irradiations at 200 W completed within 2–4 min. The crude mixture was extracted with EtOAc (3 × 25 mL) and the combined organic layer was dried over sodium sulfate, concentrated under reduced pressure and purified through a column chromatography or recrystallization, to give pure 6a–g in 86–98% yields.
6.5.1 (1-phenyl-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6a)
Yellow paste; yield 94% (0.115 g), mp: 222–224 °C; 1H NMR (300 MHz, CDCl3): δ 8.01 (1H, s), 7.70 (2H, dd, J = 7.5; 1.5 Hz), 7.50 (2H, dd, J = 7.2; 1.5 Hz), 7.42 (1H, m), 5.25 (3H, m), 3.15 (1H, dd, J = 11.2; 4.8 Hz), 2.87 (1H, dd, J = 7.7; 3.8 Hz), 1.94 (2H, m), 1.80 (2H, dd, J = 8.7; 3.5 Hz), 1.63–1.45 (12H, m), 1.34 (2H, m), 1.26 (4H, m), 1.08 (3H, s), 0.94 (3H, s), 0.89 (3H, s), 0.86 (3H, s), 0.74 (3H, s), 0.72 (3H, s), 0.44 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.7, 143.7, 143.5, 136.5, 129.7, 129.7, 129.7, 128.8, 122.5, 120.5, 120.5, 78.9, 57.3, 55.2, 47.5, 46.7, 45.8, 41.6, 41.4, 39.2, 38.7, 38.4, 36.9, 33.6, 33.0, 32.6, 32.4, 30.6, 29.6, 28.0, 27.6, 27.1, 25.7, 23.9, 23.8, 22.9, 18.2, 16.7, 15.5, 15.1; HRMS (ESI+): calcd. for (C39H56N3O3)+ [M+H]+ 614.4322, found 614.4324.
6.5.2 (1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6b)
Dark purple solid; yield 98% (0.126 g), mp: 220–221 °C; 1H NMR (300 MHz, CDCl3): δ 7.96 (1H, s), 7.62 (2H, d, J = 7.8 Hz), 7.02 (2H, d, J = 8.1 Hz), 5.25 (3H, m), 3.87 (3H, s), 3.20 (1H, dd, J = 10.2; 4.2 Hz), 2.84 (1H, dd, J = 8.7; 3.8 Hz), 2.00 (2H, m), 1.80 (2H, dd, J = 9.0; 3.0 Hz), 1.63–1.45 (10H, m), 1.33–1.19 (8H, m), 1.10 (3H, s), 0.97 (3H, s), 0.91 (3H, s), 0.89 (3H, s), 0.78 (3H, s), 0.75 (3H, s), 0.46 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.3, 159.3, 143.1, 143.0, 129.8, 122.2, 122.9, 121.6, 121.6, 114.2, 114.2, 78.4, 56.8, 55.1, 46.9, 46.2, 45.3, 41.1, 40.8, 38.7, 38.2, 37.8, 36.4, 33.2, 32.6, 32.0, 31.8, 30.1, 29.2, 27.6, 27.1, 26.6, 25.2, 23.1, 22.8, 22.4, 17.7, 16.2, 15.0, 14.7; HRMS (ESI+): calcd. for (C40H58N3O4)+ [M+H]+ 644.4428, found 644.4416.
6.5.3 (1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6c)
Dark red solid; yield 98% (0.127 g), mp: 226–227 °C; 1H NMR (300 MHz, CDCl3): δ 8.02 (1H, s), 7.69 (2H, dd, J = 6.9; 2.7 Hz), 7.51 (2H, dd, J = 6.6; 3.0 Hz), 5.28 (3H, m), 3.21 (1H, dd, J = 10.8; 4.2 Hz), 2.87 (1H, dd, J = 9.2; 3.8 Hz), 2.01 (1H, m), 1.80 (2H, dd, J = 7.8; 2.4 Hz), 1.68–1.45 (12H, m), 1.29 (3H, m), 1.18 (4H, m), 1.11 (3H, s), 0.97 (3H, s), 0.92 (3H, s), 0.90 (3H, s), 0.78 (3H, s), 0.76 (3H, s), 0.46 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.8, 143.5, 135.5, 134.6, 129.9, 129.9, 129.0, 122.5, 121.6, 121.6, 116.2, 78.9, 57.2, 55.1, 47.5, 46.7, 45.8, 41.6, 41.3, 39.2, 38.7, 38.4, 36.9, 33.8, 33.0, 32.6, 32.4, 31.8, 30.6, 28.0, 27.6, 27.1, 25.7, 23.6, 23.3, 22.9, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for (C39H55ClN3O3)+ [M+H]+ 648.3932, found 648.3924.
6.5.4 (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6d)
White solid; yield 96% (0.132 g), mp: 214–216 °C; 1H NMR (300 MHz, CDCl3): δ 8.01 (1H, s), 7.65 (2H, dd, J = 8.1; 3.4 Hz), 7.50 (2H, dd, J = 7.8; 3.2 Hz), 5.29 (3H, m), 3.21 (1H, dd, J = 10.8; 4.2 Hz), 2.87 (1H, dd, J = 9.2; 3.8 Hz), 1.99 (2H, m), 1.80 (2H, dd, J = 7.9; 2.8 Hz), 1.71–1.55 (10H, m), 1.33–1.27 (4H, m), 1.18 (4H, m), 1.11 (3H, s), 0.97 (3H, s), 0.92 (3H, s), 0.90 (3H, s), 0.78 (3H, s), 0.76 (3H, s), 0.46 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.9, 143.7, 136.1, 133.9, 129.2, 129.2, 129.0, 122.5, 120.8, 120.8, 115.9, 78.7, 56.8, 55.5, 47.6, 46.7, 45.8, 41.9, 41.3, 39.4, 38.7, 38.8, 36.7, 33.9, 33.3, 32.9, 32.4, 31.8, 30.6, 28.7, 27.9, 27.4, 25.7, 23.6, 23.3, 22.9, 18.2, 16.8, 15.2; HRMS (ESI+): calcd. for (C39H55BrN3O3)+ [M+H]+ 692. 3427, found 692.3427.
6.5.5 (1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6e)
Yellow solid; yield 90% (0.118 g), mp: 218–320 °C; 1H NMR (300 MHz, CDCl3): δ 8.02 (1H, s), 7.60 (2H, d, J = 7.9 Hz), 7.00 (2H, d, J = 8.1 Hz), 5.28 (3H, m), 3.23 (1H, dd, J = 10.8; 3.8 Hz), 2.87 (1H, dd, J = 9.6; 4.0 Hz), 2.01 (1H, m), 1.83 (2H, dd, J = 7.8; 2.6 Hz), 1.68–1.44 (12H, m), 1.29 (3H, m), 1.22 (4H, m), 1.10 (3H, s), 0.98 (3H, s), 0.92 (3H, s), 0.90 (3H, s), 0.79 (3H, s), 0.76 (3H, s), 0.49 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.6, 143.1, 135.0, 134.4, 129.6, 129.6, 129.0, 122.4, 121.4, 121.4, 116.8, 78.9, 56.8, 55.0, 47.2, 46.6, 45.5, 41.3, 41.0, 39.2, 38.7, 38.2, 36.9, 33.8, 33.0, 32.7, 32.4, 31.8, 30.9, 28.2, 27.6, 27.0, 25.7, 23.9, 23.3, 22.9, 18.2, 16.8, 15.9; HRMS (ESI+): calcd. for (C39H55N4O5)+ [M+H]+ 659. 4173, found 659.4175.
6.5.6 (1-(3-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6f)
Yellow solid; yield 92% (0.115 g), mp: 231–232 °C; 1H NMR (300 MHz, CDCl3): δ 8.02 (1H, s), 7.55 (1H, s), 7.50 (1H, d, J = 8.1 Hz), 7.39 (1H, t, J = 7.5 Hz), 7.25 (1H, d, J = 7.5 Hz), 5.28 (3H, m), 3.23 (1H, dd, J = 10.8; 4.2 Hz), 2.87 (1H, dd, J = 9.2; 3.8 Hz), 2.44 (3H, s), 1.95 (1H, td, J = 10.2; 3.8 Hz), 1.83 (2H, dd, J = 8.7; 3.3 Hz), 1.67–1.43 (10H, m), 1.38 (8H, m), 1.12 (3H, s), 1.04 (3H, s), 0.97 (3H, s), 0.94 (3H, s), 0.78 (3H, s), 0.75 (3H, s), 0.67 (1H, m), 0.45 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.7, 143.6, 143.5, 139.9, 136.9, 129.5, 129.4, 122.6, 122.4, 121.2, 117.6, 78.9, 57.3, 55.1, 47.5, 46.7, 45.8, 41.6, 41.3, 39.2, 38.7, 38.4, 36.9, 33.8, 33.0, 32.6, 32.4, 31.8, 30.6, 29.6, 28.0, 27.6, 27.1, 25.7, 23.6, 23.3, 22.9, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for (C40H58N3O3)+ [M+H]+ 628. 4478, found 628.4481.
6.5.7 (1-naphthalen-1-yl-1H-1,2,3-triazol-4-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (6g)
Dark red solid; yield 87% (0.115 g), mp: 246–247 °C; 1H NMR (300 MHz, CDCl3): δ 8.03–7.94 (3H, m), 7.65–7.50 (5H, m), 5.38 (1H, d, J = 12.9 Hz), 5.30 (1H, d, J = 13.8 Hz), 5.26 (1H, s), 3.17 (1H, dd, J = 10.8; 5.1 Hz), 2.88 (1H, dd, J = 13.5; 4.2 Hz), 1.94 (1H, m), 1.80 (2H, m), 1.71–1.57 (3H, m), 1.60–1.47 (8H, m), 1.42–1.37 (2H, m), 1.28–1.19 (6H, m), 1.12 (3H, s), 0.96 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.74 (3H, s), 0.73 (3H, s), 0.54 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.3, 143.1, 142.7, 133.7, 133.0, 129.9, 127.8, 127.8, 127.4, 126.5, 126.2, 124.4, 122.9, 121.9, 121.8, 78.4, 59.8, 57.0, 54.6, 47.0, 46.3, 45.3, 41.2, 40.8, 38.3, 38.2, 37.9, 36.4, 33.3, 32.5, 31.9, 30.1, 27.6, 27.1, 26.6, 25.2, 23.1, 22.8, 22.5, 17.7, 16.5, 15.0, 14.6; HRMS (ESI+): calcd. for (C43H58N3O3)+ [M+H]+ 664. 4478, found 664.4476.
6.6 General procedure for the synthesis of compounds 7a–g: Ru-catalyzed azide–alkyne cycloaddition
To a solution of alkyne 5 (0.1 g, 0.2 mmol) in DMF, Cp∗RuCl(PPh3)2 (5 mol%) was added at room temperature. To this mixture, aryl azide (0.4 mmol) was added and the reaction mixture was subjected to microwave irradiations at 250 W completed within 3–6 min. The crude mixture was extracted with EtOAc (3 × 25 mL) and the combined organic layer was dried over sodium sulfate, concentrated in vacuo and purified through a column chromatography or recrystallization, to give pure 7a–g in 84–96% yields.
6.6.1 (1-phenyl-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7a)
Gummy yellowish; yield 90% (0.110 g), mp: 288–289 °C; 1H NMR (300 MHz, CDCl3/CD3OD): δ 8.17 (1H, s), 7.93–7.85 (5H, m), 5.53 (1H, t, J = 3.6 Hz), 5.50 (1H, d, J = 13.5 Hz), 5.41 (1H, d, J = 13.5 Hz), 3.45 (1H, t, J = 6.3 Hz), 3.11 (1H, dd, J = 11.8; 3.8 Hz), 2.14 (2H, m), 1.93–1.85 (8H, m), 1.77–1.65 (8H, m), 1.59 (2H, m), 1.52 (2H, m), 1.42 (3H, s), 1.27 (3H, s), 1.20 (6H, s), 1.17 (3H, s), 1.06 (3H, s), 0.81 (3H, s); 13C NMR (75 MHz, CDCl3/CD3OD): δ 180.6, 146.7 139.1, 138.6, 136.4, 133.5, 133.1, 133.1, 128.1, 128.1, 126.2, 81.9, 58.6, 57.0, 52.4, 51.6, 49.1, 45.0, 44.7, 42.6, 42.0, 39.2, 38.7, 38.4, 41.9, 40.3, 37.0, 36.1, 33.4, 31.7, 31.4, 30.5, 29.5, 27.1, 26.9, 22.1, 20.5, 19.3, 18.7; HRMS (ESI+): calcd. for (C39H56N3O3)+ [M+H]+ 614.4321, found 614.4304.
6.6.2 (1-(4-methoxyphenyl)-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7b)
Dark red solid; yield 96% (0.123 g), mp: 292–294 °C; 1H NMR (300 MHz, CDCl3): δ 7.82 (1H, s), 7.47 (2H, dd, J = 6.9; 2.1 Hz), 7.05 (2H, dd, J = 6.9; 2.1 Hz), 5.27 (1H, t, J = 3.1 Hz), 5.11 (1H, d, J = 13.5 Hz), 5.06 (1H, d, J = 13.8 Hz), 3.89 (3H, s), 3.21 (1H, dd, J = 10.8; 4.0 Hz), 2.84 (1H, dd, J = 8.8; 3.4 Hz), 2.01 (1H, m), 1.80 (2H, dd, J = 8.7; 3.6 Hz), 1.66–1.45 (16H, m), 1.32 (3H, s), 1.10 (3H, s), 1.12 (3H, s), 0.99 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.78 (3H, s), 0.56 (3H, s); 13C NMR (75 MHz, CDCl3): δ 176.3, 160.1, 142.8, 134.7, 132.3, 128.3, 125.7, 125.7, 122.2, 114.2, 114.2, 78.4, 55.1, 54.7, 53.3, 47.0, 46.4, 45.2, 41.2, 40.8, 38.7, 38.2, 37.9, 36.5, 33.2, 32.4, 32.1, 31.8, 30.1, 27.6, 27.1, 26.6, 25.3, 23.0, 22.8, 22.6, 17.7, 16.3, 15.0, 14.8; HRMS (ESI+): calcd. for (C40H58N3O4)+ [M+H]+ 644.4427, found 644.4407.
6.6.3 (1-(4-chlorophenyl)-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7c)
Dark red solid; yield 94% (0.121 g), mp: 284–286 °C; 1H NMR (300 MHz, CDCl3): δ 7.85 (1H, s), 7.58–7.50 (4H, m), 5.26 (1H, t, J = 3.3 Hz), 5.16 (1H, d, J = 13.5 Hz), 5.08 (1H, d, J = 13.5 Hz), 3.23 (1H, dd, J = 10.2; 4.0 Hz), 2.84 (1H, dd, J = 11.2; 3.8 Hz), 2.04 (2H, m), 1.80 (2H, dd, J = 8.2; 3.1 Hz), 1.64–1.35 (18H, m), 1.16 (3H, s), 0.99 (3H, s), 0.91 (3H, s), 0.89 (3H, s), 0.88 (3H, s), 0.81 (3H, s), 0.53 (3H, s); 13C NMR (75 MHz, CDCl3): δ 176.8, 143.3, 135.9, 135.7, 134.4, 132.4, 129.9, 129.9, 125.9, 125.9, 122.8, 78.9, 55.2, 53.5, 47.5, 46.9, 45.7, 41.7, 41.3, 39.2, 38.7, 38.4, 37.0, 33.7, 32.9, 32.6, 32.3, 30.6, 29.6, 28.0, 27.5, 27.1, 25.8, 23.5, 23.3, 23.1, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for (C39H55ClN3O3)+ [M+H]+ 648.3932, found 648.3915.
6.6.4 (1-(4-bromophenyl)-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7d)
White solid; yield 92% (0.127 g), mp: 286–287 °C; 1H NMR (300 MHz, CDCl3): δ 7.82 (1H, s), 7.42 (2H, dd, J = 7.2; 2.6 Hz), 7.08 (2H, dd, J = 7.2; 2.4 Hz), 5.27 (1H, t, J = 3.1 Hz), 5.18 (1H, d, J = 13.5 Hz), 5.10 (1H, d, J = 13.5 Hz), 3.21 (1H, dd, J = 10.8; 4.2 Hz), 2.86 (1H, dd, J = 9.2; 3.8 Hz), 2.01 (2H, m), 1.80 (2H, dd, J = 7.9; 2.6 Hz), 1.69–1.39 (12H, m), 1.31 (2H, m), 1.18 (4H, m), 1.11 (3H, s), 0.99 (3H, s), 0.95 (3H, s), 0.93 (3H, s), 0.78 (3H, s), 0.76 (3H, s), 0.54 (3H, s); 13C NMR (75 MHz, CDCl3): δ 178.2, 144.7, 136.1, 133.9, 129.8, 129.8, 129.0, 122.5, 120.4, 120.4, 116.5, 78.6, 56.7, 55.4, 47.6, 46.7, 45.2, 41.9, 41.3, 39.4, 38.7, 38.8, 36.7, 33.9, 33.3, 32.9, 32.4, 31.8, 30.6, 28.7, 27.9, 27.7, 25.7, 23.6, 23.3, 22.9, 18.2, 16.9, 15.8; HRMS (ESI+): calcd. for (C39H55BrN3O3)+ [M+H]+ 692.3427, found 692.3420.
6.6.5 (1-(4-nitrophenyl)-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7e)
Yellow solid; yield 96% (0.126 g), mp: 294–296 °C; 1H NMR (300 MHz, CDCl3): δ 7.82 (1H, s), 7.49 (2H, dd, J = 6.9; 2.1 Hz), 7.11 (2H, dd, J = 6.9; 2.1 Hz), 5.27 (1H, t, J = 3.3 Hz), 5.08 (2H, m), 3.23 (1H, dd, J = 10.8; 4.0 Hz), 2.86 (1H, dd, J = 8.8; 3.4 Hz), 2.01 (2H, m), 1.80 (2H, dd, J = 8.7; 3.6 Hz), 1.60–1.45 (12H, m), 1.40 (4H, m), 1.32 (2H, s), 1.10 (3H, s), 1.12 (3H, s), 0.99 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.78 (3H, s), 0.56 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.3, 159.8, 142.6, 134.7, 132.3, 128.3, 125.9, 125.9, 122.2, 116.2, 116.2, 78.4, 55.1, 54.7, 47.0, 46.4, 45.2, 41.2, 40.8, 38.7, 38.2, 37.9, 36.5, 33.2, 32.4, 32.1, 31.8, 30.1, 27.6, 27.1, 26.6, 25.3, 23.5, 22.8, 22.6, 17.9, 16.6, 15.9, 15.5; HRMS (ESI+): calcd. for (C39H55N4O5)+ [M+H]+ 659.4172, found 659.4163.
6.6.6 (1-(3-methylphenyl)-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7f)
Dark red solid; yield 92% (0.115 g), mp: 296–297 °C; 1H NMR (300 MHz, CDCl3): δ 7.84 (1H, s), 7.41–7.26 (4H, m), 5.27 (1H, t, J = 3.3 Hz), 5.15 (1H, d, J = 13.5 Hz), 5.10 (1H, d, J = 13.5 Hz), 3.21 (1H, dd, J = 10.8; 4.2 Hz), 2.84 (1H, dd, J = 9.2; 3.8 Hz), 2.46 (3H, s), 2.00 (2H, m), 1.85 (2H, dd, J = 8.7; 3.3 Hz), 1.74–1.42 (13H, m), 1.38 (4H, m), 1.12 (3H, s), 0.99 (3H, s), 0.91 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.78 (3H, s), 0.71 (1H, m), 0.56 (3H, s); 13C NMR (75 MHz, CDCl3): δ 176.8, 143.3, 139.9, 135.8, 132.4, 130.5, 129.9, 129.7, 129.2, 122.7, 121.7, 78.9, 55.2, 53.8, 47.5, 46.7, 45.8, 41.6, 41.3, 39.2, 38.7, 38.4, 36.9, 33.8, 33.0, 32.6, 32.4, 31.8, 30.6, 29.6, 28.0, 27.6, 27.1, 25.7, 23.6, 23.3, 22.9, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for (C40H58N3O3)+ [M+H]+ 628.4478, found 628.4502.
6.6.7 (1-naphthalen-1-yl-1H-1,2,3-triazol-5-yl)methyl-(3β)-3-hydroxyolean-12-en-28-oate (7g)
Dark red solid; yield 84% (0.111 g), mp: 295–297 °C; 1H NMR (300 MHz, CDCl3): δ 8.08 (1H, d, J = 7.6 Hz), 7.99 (1H, d, J = 7.8 Hz), 7.96 (1H, s), 7.65–7.50 (4H, m), 7.22 (1H, d, J = 8.4 Hz), 5.17 (1H, s), 4.99 (1H, d, J = 13.4 Hz), 4.29 (1H, d, J = 13.8 Hz), 3.22 (1H, dd, J = 10.8; 5.4 Hz), 2.73 (1H, dd, J = 13.5; 4.2 Hz), 1.83 (3H, m), 1.71–1.42 (11H, m), 1.42–1.35 (6H, m), 1.28–1.19 (2H, m), 1.27 (3H, s), 1.06 (3H, s), 0.98 (3H, s), 0.90 (3H, s), 0.85 (3H, s), 0.80 (3H, s), 0.48 (3H, s); 13C NMR (75 MHz, CDCl3): δ 177.3, 143.1, 142.7, 133.7, 133.0, 129.9, 127.8, 127.8, 127.4, 126.5, 126.2, 124.4, 122.9, 121.9, 121.8, 78.4, 59.8, 57.0, 54.6, 47.0, 46.3, 45.3, 41.2, 40.8, 38.3, 38.2, 37.9, 36.4, 33.3, 32.5, 31.9, 30.1, 27.6, 27.1, 26.6, 25.2, 23.1, 22.8, 22.5, 17.7, 16.5, 15.0, 14.6; HRMS (ESI+): calcd. for (C43H58N3O3)+ [M+H]+ 664.4478, found 664.4482.
6.7 Biological assay
Natural pentacyclic triterpenoid (Oleanolic acid 1) and most of the synthesized triazoles type 6 and 7 were dissolved in dimethyl sulfoxide (DMSO) and added into the medium at final concentrations of 10, 30 and 100 μM. The final concentration of DMSO was 0.33% and was determined to have no cytotoxicity.
6.7.1 Determination of anticancer activity in EMT-6 and SW480 cancer cell lines
Murine mammary carcinoma cell line EMT-6 and human colorectal adenocarcinoma cell line SW480, purchased from American Type Culture Collection (ATCC, Manassas, VA), were cultured in DMEM supplemented with 10% of fetal bovine serum and penicillin (100 U/mL), streptomycin (100 μg/mL), and amphotericin B (250 ng/mL) and placed in CO2 incubator with 5% of CO2 at 37 °C. Cells were seeded in a 96-well microplate at 3.125 × 104 cells/mL and treated with compounds for 48 h. Doxorubicin, etoposide, 5-fluorouracil and methotrexate (10 μM) were used as anticancer references. The anticancer activity of compounds and drug references was determined using XTT assay (Jost et al., 1992; Manase et al., 2014). This assay is based on the conversion of the water-soluble XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium) inner salt) reagent, in the presence of the electron coupling reagent PMS (phenazine methylsulfate) to an orange formazan product by metabolically active cells. The amount of formazan produced was detected by the measurement of the absorbance at 499 nm and a reference wavelength was used at 660 nm on a microplate reader Infinite M200 Pro TECAN. Cell viability is expressed as a percentage of control, which was taken as 100%.
6.7.2 Determination of pro-inflammatory IL-1β cytokine production in PBMCs
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from healthy donors by density gradient centrifugation (Pancoll human, d.1.077 g/mL). Recovered PBMCs were washed three times in Dulbecco’s phosphate buffered saline, seeded in a 96-well microplate at 6.67 × 105 cells/mL in RPMI-1640 containing 10% fetal bovine serum, penicillin (100 U/mL), streptomycin (100 μg/mL), amphotericin B (250 ng/mL), and incubated at 5% CO2 and 37 °C. PBMCs were treated with compounds (10, 30, 100 μM) and then were stimulated for 24 h with LPS (Escherichia coli, 0128:B12, Sigma) (10 ng/mL) (Schindler et al., 1990; Shah et al., 2010). Three anti-inflammatory references were tested in the same conditions: ZVAD (5 μM), dexamethasone (DEXA, 1 μM) and prednisolone (PRED, 70 μM). After incubation, the supernatants were harvested and kept at −20 °C until use. Viability of PBMCs was assessed by XTT assay. Secretion IL-1β was measured only in the culture supernatants of PBMCs treated with compounds that showed low toxicity, using a sandwich enzyme-linked immunosorbent assay (ELISA) method (eBioscience, San Diego, USA), according to manufacturer instructions.
Acknowledgments
The authors are grateful to Miss Amna Benzarti, NMR service at the Faculty of Monastir, University of Monastir for the 1D and 2D NMR analysis and to the Ministry of Higher Education and Scientific Research of Tunisia for financial support (LR11ES39).
References
- Int. J. Biol. Macromol.. 2012;51:56-63.
- Chem. Asian. J.. 2011;6:2696-2718.
- Bull. Korean Chem. Soc.. 2004;25:420-422.
- Bioorg. Med. Chem. Lett.. 2008;18:1195-1198.
- Bioorg. Med. Chem.. 2011;19:4043-4050.
- Eur. J. Pharm. Sci.. 2012;47:549-555.
- Org. Chem. Port.. 2008;130:8923-8930.
- Bioorg. Med. Chem. Lett.. 2006;16:2915-2919.
- Food Chem.. 2010;118:751-756.
- Food. Chem.. 2015;183:8-17.
- Org. Lett.. 2005;7:1469-1472.
- Food. Chem.. 2013;141:1881-1887.
- J. Med. Chem.. 2008;51:6263-6270.
- Eur. J. Med. Chem.. 2014;83:601-608.
- Food. Chem.. 2015;167:468-474.
- C.R. Chem.. 2003;6:473-483.
- J. Immunol. Methods. 1992;147:153-165.
- Bioorg. Med. Chem. Lett.. 2008;18:1468-1473.
- Bioorg. Med. Chem. Lett.. 2008;18:1131-1134.
- Revisited Org. Lett.. 2004;6:1237-1240.
- Tetrahedron Lett.. 2009;50:2065-2068.
- Tetrahedron. 1998;54:5745-5752.
- Chin. Chem. Lett.. 2014;25:1161-1164.
- J. Ethnopharmacol.. 2005;100:92-94.
- J. Ethnopharmacol.. 1995;49:57-68.
- Phytochemistry. 2014;100:150-155.
- Heterocycles. 1996;43:2643-2655.
- Eur. J. Med. Chem.. 2013;66:238-245.
- Life Sci.. 2006;79:1349-1356.
- Blood. 1990;1:40-47.
- Bioorg. Med. Chem.. 2010;18:7458-7474.
- Nat. Prod. Res.. 2010;24:1177-1188.
- Carbohydr. Res.. 2010;345:1641-1648.
- Biotechnol. Bioprocess. Eng.. 2010;15:1038-1046.
- Tetrahedron Lett.. 2010;51:2737-2740.
- Tetrahedron. 1997;53:3831-3842.
- Eur. J. Med. Chem.. 2010;45:4631-4639.
- Org. Biomol. Chem.. 2015;13:1507-1514.
- Phytother. Res.. 2001;15:589-592.
